Trial Profile

A Phase III clinical trial (superiority study) of DFP-14323 in combination with afatinib versus afatinib alone in stage III/IV non-small cell lung cancer patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jul 2024 According to Delta-Fly Pharma media release, company announced initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323, the company will accelerate the progress of the trial by expanding this Phase III clinical trial outside of Japan to Asian countries with large numbers of EGFR mutation-positive non-small cell lung cancer patients, and at the same time, promote out-licensing activities to Asian pharmaceutical companies.
03 Jul 2024 Status changed from planning to recruiting as per Delta-Fly Pharma media release
07 Feb 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com